Dew, Thanks for the comments and info. I was unaware that Axiokine was a second generation product.
I agree with you that it is mystifying that neutralizing Abs were not detected until phase III.
IMO the neutralizing ABs are a potential problem with any recombinant protein-->recombinant proteins like EPO, GH, etc., monoclonal antibodies, and fusion proteins.
The Regeneron Trap is a fusion of an Fc domain and extracellular components of VEGFR receptors. Fusion proteins are non-endogenous proteins, and I have theoretical concerns that neutralizing Abs could form. Maybe my concerns are over blown. We will just have to see the clinical data. Neutralizing ABs are not a problem with Enbrel, a soluble receptor/fusion protein that has done very well. biophud
Market Data 
Markets 
AI
